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The PSORS1 locus in the human major histocom-
patibility complex on 6p21 has been consistently
associated with psoriasis in populations of diverse
ethnicity. The HLA-C allele Cw*0602, located
therein, has been found in up to 67% of psoriasis
patients but is no longer considered a candidate gene
in itself. The a-helix coiled-coil rod homolog gene
(HCR, previously Pg8) is located 110 kb from the
HLA-C gene, positioned between the CDSN and SC1
genes, within a region thought to harbor a psoriasis
gene (PSORS1). We investigated the HCR gene for
disease association by direct sequencing of nine poly-
merase chain reaction products ampli®ed from a ser-
ies of Swedish psoriasis patients and controls. We
found that HCR is a very polymorphic gene with 25
polymorphisms in the open reading frame alone, of
which 10 demonstrated disease association; however,
the relationship between HCR polymorphisms and
HLA-Cw*0602 indicates that HCR cannot truly be
considered a likely candidate gene. We investigated
Cw*0602 association while stratifying for HCR single
nucleotide polymorphisms. We also investigated
HCR single nucleotide polymorphism association
with the disease while stratifying for the presence of
Cw*0602. We found that whichever single nucleotide
polymorphism that was strati®ed for, there was still a
strongly signi®cant Cw*0602 association with psoria-
sis; however, when we strati®ed for Cw*0602 pres-
ence, only one silent polymorphism showed
signi®cant association. In a recent similar study this
polymorphism was actually found to be decreased in
psoriasis individuals. Thus we conclude that HCR
polymorphisms display association with psoriasis due
to linkage disequilibrium with Cw*0602 and is,
therefore, unlikely to be directly involved in the
development of psoriasis. Key words: complex disease/
genetics/HLA-C/skin disease. J Invest Dermatol 116:750±
754, 2001
P
soriasis is a common chronic skin disorder that manifests
itself as red scaly skin lesions commonly affecting the
elbows, knees, and scalp, whereas other complications
such as arthritis also occur. The skin lesions are
characterized by in®ltration of in¯ammatory cells into
the dermis and abnormal keratinocyte proliferation. Psoriasis does
not generally affect the overall health of an individual; however, the
social and psychosomatic effects of the disorder can be substantial
(Linden and Weinstein, 1999). Prevalence varies with race and
geography, being highest in Norway and northern Russia (5±10%)
and lowest in, for example Eskimos and native Americans (0±0.3%)
(Bhalerao and Bowcock, 1998). In the Swedish population it
displays a moderate prevalence of 2±3% (Hellgren, 1967).
Psoriasis can be triggered by such environmental factors as
streptococcal throat infections, trauma, and stress (Henseler, 1997);
however, there is a strong genetic component in the susceptibility
to the disease, with the concordance rate in monozygotic twins
being between 35 and 70%, compared with 4±38% in dizygotic
twins in several independent studies (Farber et al, 1974; Brandrup et
al, 1982; Duffy et al, 1993). Psoriasis does not display a simple mode
of inheritance and is classi®ed as a complex disease, i.e., involving
an interplay of multiple genetic factors, which is modi®ed to a
greater or lesser degree by environmental in¯uences (Henseler,
1997). Multiple loci are suspected to harbor psoriasis susceptibility
genes, e.g., PSORS1 on 6p21.3, PSORS2 on distal 17q, PSORS3
on 4q12±q13, PSORS4 on 1cen-q21, PSORS5 on 3q21, and other
associated loci (Henseler, 1997; http://www.ncbi.nlm.nih.gov/
Omim). Linkage analysis and psoriasis association studies have
indicated that the PSORS1 and PSORS2 loci appear to be
important in the Swedish population, whereas PSORS5 seems to
be unique to psoriatics in south-western Sweden (Enlund et al,
1999a, b; Samuelsson et al, 1999); however, it is the PSORS1 locus
that alone has been consistently found to be associated with
psoriasis populations of diverse ethnicity. PSORS1 is composed of
the major histocompatibility complex on 6p21, which contains the
numerous human leukocyte antigen (HLA) genes (The MHC
Sequencing Consortium, 1999). The association between psoriasis
and certain HLA alleles supports the hypothesis that psoriasis is a T
cell mediated, autoimmune disorder (Elder et al, 1994). In 1972 the
®rst demonstration of psoriasis association with a HLA antigen was
published that showed an increased frequency of HLA-B17 and
HLA-B13 when compared with controls (Russell et al, 1972). Since
then, antigens/alleles in this region have shown high association
with psoriasis, e.g., HLA-Cw6, DR7, B13, and B57. It is the Cw6
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antigen (Cw*0602 allele of HLA-C) that has exhibited the highest
association and especially so in early onset psoriasis. Cw*0602 is
present in 1±20% of the population (Mallon et al, 1999), but has
been consistently found in increased frequencies in psoriasis, being
as high as 67% in Swedish psoriasis patients; however, this increased
frequency likely indicates that Cw*0602 is in linkage disequilib-
rium with the psoriasis gene, as only 10% of Cw*0602-positive
individuals develop the disease (Nair et al, 2000). Other lines of
evidence have also indicated that HLA-C is not the PSORS1 gene
(Jenisch et al, 1998, 1999b; Leder et al, 1998). Thus it is more likely
that the PSORS1 gene is positioned in the vicinity of HLA-C.
Despite being located in the most gene dense region of the human
genome, HLA-C is surrounded by a large number of pseudogenes
and we therefore lack candidates. The CDSN (formerly known as
the S gene) and SC1 genes have been investigated for association
with psoriasis (Jenisch et al, 1999a; EnerbaÈck et al, 2000; Teraoka et
al, 2000). Both CDSN and SC1, located 133 kb and 110 kb
telomeric of the HLA-C showed high association with psoriasis, but
are no longer regarded as likely candidate genes (Nair et al, 2000).
The a-helix coiled-coil rod homolog gene (HCR, previously
Pg8) is located 110 kb from the HLA-C gene, positioned between
the CDSN and SC1 genes. Little is known about this novel gene and
comparison between the various genomic and expressed sequence
tag (EST) sequences shows that it appears to be very polymorphic.
Therefore, we considered this gene to be a putative candidate
psoriasis gene. Here, we analyzed a series of Swedish psoriasis
patients for the presence and frequency of polymorphisms and
compared them with population-matched controls. We found that
several single nucleotide polymorphisms (SNP) display signi®cant
association with psoriasis, but that this association can be explained
to a large degree by linkage disequilibrium with Cw*0602.
MATERIALS AND METHODS
Patient and control individuals The 42 psoriasis individuals who
form the basis of this study were recruited from the Swedish Psoriasis
Association. Each person was individually examined by an experienced
dermatologist (A.I.) to con®rm the diagnosis of psoriasis. This group has
an equal sex distribution and show a mean, median, and range of age of
onset of 19, 16, and 6±51 y, respectively. Control individuals used in
this study consisted of 38 population-matched controls from Sweden.
The study was approved by the Regional Committees of Ethics in
Stockholm and Gothenburg and all samples were used with informed
consent.
Bioinformatics Exon±intron structure of HCR was obtained by
plotting the genomic sequence (accession no. AB029343) against the
mRNA sequence (accession no. NM_019052) of the HCR gene. Dot
matrix plots were produced using the Dotter program (Sonnhammer and
Durbin, 1995). Primer design was utilized by blocking repetitive
sequences using RepeatMasker (repeat-masker.genome.washington.edu)
and performed by the Oligo 5.0 program (Molecular Biology Insights,
Cascade, CO). To analyze the putative function of HCR the following
online tools were utilized: the Blast family for homology searches;
Scanprosite (http://www.expasy.ch/prosite), Pfam (pfam.wustl.edu), Blocks
(http://www.blocks.fhcrc.org), and Smart (smart.embl-heidelberg.de) to
search for known protein families and domains; Coils (http://
www.ch.embnet.org), Paircoil (nightingale.lcs.mit.edu/cgi-bin/score) and
Multicoil (nightingale. lcs.mit.edu/cgi-bin/multicoil) to detect coiled-
coiled domains; and Psort (psort.nibb.ac.jp:8800) in the prediction of
protein sorting signals and localization sites.
Polymorphism analysis To facilitate polymorphism analysis, we
ampli®ed all 16 exons of the HCR gene from 42 psoriasis individuals and
38 controls in nine separate polymerase chain reaction products using
speci®c primers (Table I). Ampli®cation was achieved using Taq
polymerase (Promega, Madison, WI) using 100 ng control or patient
DNA as template, in a 20 ml reaction in a 96-well Robocycler
thermocycler (Stratagene, La Jolla, CA) under standard conditions.
Ampli®ed products were puri®ed using Microcon polymerase chain
reaction columns (Millipore, Bedford, MA), sequenced using DYEnamic
sequencing chemistry according to the recommendations of the supplier
(Amersham Pharmacia Biotech, Sweden) in a 6 ml reaction in a 96-well
Robocycler thermocycler in both directions using the primers utilized in
polymerase chain reaction ampli®cation (Table I). Products of sequencing
reactions were separated on LongRanger polyacrylamide (BMA
Bioproducts, Rockland, ME) 96-well gels on ABI 377 sequencers (Perkin
Elmer, Norwalk, CT). Chromatograms were imported and assembled
using the Pregap4 and Gap4 programs of the Staden package (Staden,
1994). Resulting sequences were compared against the genomic sequence
of HCR (accession no. AB029343) and polymorphisms were detected
using the TRACE_DIFF program of the same package; a program option
that compares average chromatogram peak height against an individual's
chromatogram peak height and visualizes differences (i.e., polymorphisms)
(Bon®eld et al, 1998). Identi®cation of novel polymorphisms was
performed on an ongoing basis, as each individual was being characterized
for HCR SNP content. Sequences with novel polymorphisms or
ambiguous sequence were re-sequenced and reanalyzed. HLA-Cw*0602
status was determined by phototyping as described previously (Bunce et al,
1995).
Statistical analysis Each HCR SNP was categorized according to
presence or absence of the rarer nucleotide in the control group.
Association with psoriasis was tested for each SNP on 2 3 2
contingency tables by Fisher's exact test. Linkage disequilibrium between
Cw*0602 and the SNP were tested similarly. Association between
psoriasis and Cw*0602 using SNP as confounders as well as association
between psoriasis and SNP using Cw*0602 status as a confounder was
tested with the Mantel±Haenszel test. Correction for multiple testing was
performed by a randomization based step-down procedure (Westfall and
Young, 1993).
RESULTS
Gene structure and expression The HCR gene is a novel gene
that is represented only in GenBank by a number of both genomic
and mRNA entries. In order to obtain the genomic structure of this
gene we performed a dot-plot of these entries (accession no.
AB029343vs accession no. NM_019052) and determined that
HCR is composed of 16 exons distributed over 14.7 kb. A search
using the full cDNA (accession no. NM_019052) against the EST
database, dbEST, revealed that HCR is expressed widely, with EST
from brain, colon, germ cell, kidney, lung, ovary, parathyroid,
testis, uterus, head/neck, placenta, and thymus being present. Note
that this is not an exhaustive search but an indication of expression
Table I. Primers used in ampli®cation and sequencing of the HCR gene
Exon Forward Reverse Size (bp)
1 AGGGGAGTGGTGGTTGTCTC GGAGCAAAATGGCAGAATGAT 760
2 CTATGTTTATGCCCTCAACTA ACTGCCCTCCACAATAC 694
3 and 4 TTGGTTGGGTCATTCTCTAAG CCAACCTGATCCCTAAGTCT 550
5 and 6 GAGGAGCGTGTAGAGCACA TCTGTTTACTTGCGTGTTCTG 774
7 and 8 CCCTGCATGGCATTCTTACAG CCCCAGGAAAAGAAACGAACA 603
9 and 10 ACAGGATTAGAGGGAGTTGTC GACGGGGAAGAGAAAGAGT 594
11,12 and 13 GCTGGGTGATTTCTCCTGACT ACCGGCCATATGCTGTTTC 856
14 and 15 CCCAGCGTTTGTTCCTGTCTT CCTCGAAGGACCGCAGAGAA 641
16 AGCCCTGTTTCCTCTGTAACC CCCAAACATTTCCAAAGCTG 500
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range. HCR also appears to be expressed in other species as EST
deriving from the bovine, porcine, and murine orthologs were also
seen. There is disagreement between entries in GenBank as to the
true length of the HCR mRNA and protein; however comparison
of the bovine, porcine, and murine ortholog with human indicates
that the ®rst methionine in the longest cDNA sequence online
(accession no. NM_019052) is conserved and is, therefore, likely to
initiate the HCR protein, despite lacking a proper Kosac sequence
(ACCATGG). Human and bovine EST in the database also appear
to support this longer mRNA form of HCR.
Putative protein function The 2.6 kb transcript of HCR
encodes a 782 AA protein of unknown function. We analyzed
this protein using the various prediction programs available online
(see Materials and Methods). Despite deriving its name from its
similarity to structural proteins, HCR appears to be a protein that
functions mainly in the nucleus as it was predicted to contain
nuclear localization signals by a number of analyses in Psort
(Reinhardt and Hubbard, 1998). Furthermore, it was shown to
contain leucine zipper motifs, indicating that it possibly dimerizes
and interacts with DNA. This is supported by the prediction of the
presence of multiple coiled-coil domains located throughout the
protein. Using this information, one can make a tentative
prediction that HCR functions as a transcription regulator.
HCR is a highly polymorphic gene To investigate the
presence of polymorphisms in HCR, we sequenced all 16 exons
from both directions in 42 patients and 38 controls. This revealed
that HCR is a very polymorphic gene, with a total of 25
polymorphisms located along the 2.4 kb open reading frame
(Table II). These polymorphisms coded for 13 amino acid (AA)
changes (eight nonconservative changes), whereas the remaining 12
polymorphisms were silent. The distribution of polymorphisms was
not restricted to any particular region of the reading frames as they
were spread throughout the exons. Exons 2, 8, and 15, however,
were found to contain over half of the polymorphisms combined.
All of the polymorphisms were SNP. The SNP at +1328 and
+1329 appear to occur in the same allele, but as only heterozygotes
were observed they may represent separate alleles. This would
imply that an allele that carries the SNP +1329 alone would encode
a stop codon and truncate the protein at AA 416 (W417X). All
polymorphisms were con®rmed by sequencing of both strands. In
addition, HLA-Cw*0602 status was determined and we found that
69% of psoriasis patients and 18% of controls were positive for
Cw*0602
Polymorphisms in HCR associate with psoriasis When the
polymorphisms of the HCR gene were compared between the
control and patient populations a signi®cant difference in frequency
of several SNP was observed (Table III). The SNP +1328 and
+1364, were found in 98% and 86% of patients, compared with
61% and 37% of controls, giving odds ratios of 27 (CI 3.3±586) and
10.3 (CI 3.1±36), respectively (Table III). Although these are
higher than the odds ratio of 9.9 (CI 3.1±33), which was obtained
for Cw*0602 in this study, the con®dence intervals are wide and
overlapping. The prevalence of Cw*0602 in our control group is
also higher than normally expected in the Swedish population (18%
vs 9±12%) (EnerbaÈck et al, 1997). The ®ve SNP at positions +386,
+404, +1328, +1364, and +1802 appear to constitute a single allele
as they consistently cosegregate in both patients and controls. Three
of these SNP, +386, +404, and +1328, each encode a tryptophan
(W) to arginine (R) change. This grouping of SNP was found in
38% of the controls compared with 69% in patients. In controls, the
percentage of individuals positive for this SNP group, which were
Cw*0602 positive, was 36%, whereas in patients that number rose
to 97%. Most useful in discerning this SNP group or ``allele'' were
several patients who were homozygous for the above-mentioned
group of polymorphisms. It should be mentioned, however, that in
order to con®rm allele status, pedigree data would be required.
No signi®cant association was seen between the presence of
HCR SNP and age of onset, severity, or lesion location in psoriasis
patients. Association between psoriasis and Cw*0602 using SNP as
confounders, as well as association between psoriasis and SNP using
Cw*0602 status as confounder was investigated (Mantel±Haenszel
test). A strongly signi®cant Cw*0602 association with psoriasis was
found upon strati®cation for all SNP. Only one SNP (+1364)
showed a signi®cant association with psoriasis (p = 0.001) upon
strati®cation for Cw*0602 presence. HCR SNP and Cw*0602 are
not independently distributed between controls and psoriasis
individuals and some SNP display strong linkage disequilibrium
with Cw*0602 (Table IV).
DISCUSSION
The HLA-C allele, Cw*0602, has consistently shown a strong
association with psoriasis and appears to affect the age at onset of
psoriasis (EnerbaÈck et al, 1997). Despite being present in up to 67%
of psoriasis patients, it is now believed that this allele does not
represent a major causative factor in the development of the disease.
On the contrary, it is thought that the increase of Cw*0602 in
psoriasis is due to linkage disequilibrium with a major factor located
nearby (Jenisch et al, 1998; Nair et al, 2000). Therefore, in recent
years efforts have been underway to screen systematically the
neighboring genes for involvement in this disease. The TCF19,
POU5F1, and HLA-B genes have been ruled out as candidate genes
(Nair et al, 2000; Teraoka et al, 2000). The corneodesmosin gene,
CDSN, was found to encode two alleles CD2 and CD3, which
were associated with psoriasis. Controversy, however, surrounds
whether these represent true a association or linkage disequilibrium
with Cw*0602 as both are found on psoriasis-associated Cw*0602-
positive haplotypes (Jenisch et al, 1999a; Tazi Ahnini et al, 1999;
EnerbaÈck et al, 2000; Nair et al, 2000). Identi®cation of the major
psoriasis gene is complicated by heterogeneity and the realization
Table II. Twenty-®ve polymorphisms were found in the






384/2195 G®A Arg®Gln (R102Q) Exon 2
386/2197 C®T Trp®Arg (W103R) Exon 2
404/2215 C®T Trp®Arg (W109R) Exon 2
556/2367 C®T No change Exon 2
571/2382 C®G Ser®Arg (S164R) Exon 2
614/5809 T®A Leu®Glu (L179Q) Exon 3
850/6142 C®G No change Exon 4
904/6196 A®C Glu®Asp (E275D) Exon 4
1178/8206 G®A Ala®Thr (A367T) Exon 7




G®A Trp®Gly (W417Q) Exon 8
1354/8488 C®T No change Exon 8
1364/8498 C®T No change Exon 8
1426/11148 G®A No change Exon 9
1471/11193 C®A No change Exon 9
1579/11648 T®C No change Exon 11
1601/11670 C®T No change Exon 11
1802/11963 G®T Gly®Cys (G575C) Exon 12
1959/12216 G®A Arg®Gln (R627Q) Exon 13
1990/13520 G®A No change Exon 14
2254/13911 A®G No change Exon 15
2257/13914 A®T No change Exon 15
2277/13934 C®T Ala®Val (A733V) Exon 15
2278/13935 A®G No change Exon 15
2406/14309 C ®G Ser®Cys (S776C) Exon 16
aAmpli®ed products from 42 patients and 38 controls were sequenced and ana-
lyzed for the presence of polymorphisms.
bAccording to accession no. NM_019052/AB029343, respectively.
cAmino acid no. according to the ®rst methionine in accession no.
NM_019052.
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that most of the present-day HLA haplotypes are derived from a
®nite group (» 20) of ancestral haplotypes (Degli-Esposti et al,
1992). One should, therefore, consider this when investigating
association in this region, as this implies nonrandom distribution
and association of alleles.
Here we investigate the HCR gene, which is located between
the TCF19 and CDSN genes, 110 kb from HLA-C. We
demonstrate that polymorphisms in the HCR gene, located in
the HLA region on chromosome 6p21, show strong association
with psoriasis in the Swedish population. A group of HCR SNP,
which encode a protein containing no less than three nonconser-
vative AA changes when compared with the wild-type protein,
appears to be enriched in Swedish psoriatics. Furthermore, the SNP
+1328 and +1364 gave odds ratios of 27 and 10.3, respectively
(Table III), which are higher than the odds ratio of 9.9 that was
obtained for Cw*0602 in this study (CI 3.3±586, 3.1±36, 3.1±33,
respectively).
Recently, a study investigating the HCR gene in psoriasis in the
Finnish population has been published (Asumalahti et al, 2000).
They report a truncated form of the protein starting from the
second methionine and thus lacking the ®rst 26 AA. Two SNP in
the HCR gene were found to associate strongly with psoriasis in a
Finnish population, albeit at a lower level than we observe (48%
compared with 69%). These SNP (+251 and +269 according to
their coordinates) correspond to the ®rst two SNP of the SNP
grouping, which appears to be enriched in the Swedish psoriatic
population. The study also demonstrated that, although HCR is not
normally expressed in the skin, it shows high expression levels in
psoriasis skin. The combination of these disease-associated SNP and
their demonstration of ectopic expression of HCR mRNA in
psoriasis lesions led the authors to conclude that HCR represents a
good candidate psoriasis gene (Asumalahti et al, 2000).
One must, however, address the relationship between the
various HCR SNP and HLA-Cw*0602 in order to investigate
whether HCR can truly be considered a likely candidate gene. In
the current study the psoriasis-associated HCR SNP group +386/
+404/+1328/+1364/+1802 was present in 37% of the control
population. Of these individuals only 36% were also Cw*0602.
Whereas in psoriasis patients 69% were positive for these SNP, of
which 97% were also positive for Cw*0602. Thus one can argue
that it is the haplotype HCR +386/+404/+1328/+1364/+1802-
HLA-Cw*0602 that appears to be more important in psoriasis than
the SNP group HCR +386/+404/+1328/+1364/+1802 itself.
As mentioned above, the distribution of alleles in the HLA
region is nonrandom. For example, the extended psoriasis-associ-
ated haplotype B57-Cw*0602-CD2 is derived from the ancient
haplotype EH57.1 (Jenisch et al, 1999a). Thus, if by chance an allele
is located in an ancient haplotype, which is associated with psoriasis,
then noncausal disease association will occur by linkage disequi-
Table III. HCR SNP associate with psoriasisa
Exon Baseb Polymorphism Controls (no.) Patients (no.) OR 95% CI p-value (corr)c
2 384 G®A 5% (2/38) 21% (9/42)
386 C®T 37% (14/38) 69% (29/42) 3.8 1.4±11 0.007 (0.04)
404 C®T 37% (14/38) 69% (29/42) 3.8 1.4±11 0.007 (0.04)
556 C®T 29% (11/38) 10% (4/42) 0.29 0.06±1 0.04 (NS)
571 C®G 68% (26/38) 64% (27/42)
3 614 T®A 0% (0/38) 12% (5/42)
4 850 C®G 29% (11/38) 41% (17/42)
904 A®C 63% (24/38) 31% (13/42) 0.26 0.09±0.7 0.007 (0.04)
7 1178 G®A 3% (1/38) 5% (2/42)
8 1328 C®T 61% (23/38) 98% (41/42) 27 3.3±586 0.00003 (0.0004)
1329 G®A 3% (1/38) 7% (3/42)
1354 C®T 29% (11/38) 24% (10/42)
1364 C®T 37% (14/38) 86% (36/42) 10.3 3.1±36 0.000008 (0.0001)
9 1426 G®A 5% (2/38) 0% (0/42)
1471 C®A 0% (0/38) 21% (9/42) 1.8 ± inf 0.003 (0.02)
11 1579 T®C 3% (1/38) 2% (1/42)
1601 C®T 3% (1/38) 2% (1/42)
12 1802 G®T 45% (17/38) 74% (31/42) 3.5 1.2±10 0.012 (NS)
13 1959 G®A 8% (3/38) 10% (4/42)
14 1990 G®A 29% (11/38) 50% (21/42)
15 2254 A®G 0% (0/38) 2% (1/42)
2257 A®T 29% (11/38) 7% (3/42) 0.19 0.04±0.8 0.017 (NS)
2277 C®T 0% (0/38) 2% (1/42)
2278 A®G 0% (0/38) 2% (1/42)
16 2406 C®G 50% (19/38) 86% (36/42) 6.0 1.8±20 0.00072 (0.004)
HLA-Cw*0602 18% (7/38) 69% (29/42) 9.9 3.1±33 0.0000057 (0.0001)
aThe frequency of SNP in patients were compared with that of controls.
bAccording to accession no. NM_019052.
cDetermined by Fisher's exact test and randomization based step-down procedure (values in parentheses indicate p-values corrected for multiple testing).
OR, odds ratio; CI, con®dence interval; NS, not signi®cant.
Table IV. HCR SNP vary according to CW *0602 and
psoriasis status.a
Exon Baseb Polymorphism Controls (no.) Patients (no.)
CW6± CW6+ CW6± CW6+
2 386 C®T 9 5 1 28
404 C®T 9 5 1 28
556 C®T 9 2 2 2
4 904 A®C 20 4 8 5
8 1328 C®T 17 6 12 29
1364 C®T 11 3 10 26
9 1471 C®A 0 0 4 5
12 1802 G®T 12 5 3 28
15 2257 A®T 9 2 1 2
16 2406 C®G 13 6 12 24
aOnly psoriasis associated SNP are shown, 38 controls and 42 patients studied.
bAccording to accession no. NM_019052.
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librium. This appears to be the case with HCR. Both Cw*0602 and
HCR SNP show association with psoriasis and are also in tight
linkage disequilibrium. We investigated Cw*0602 association
while stratifying for HCR SNP. We also investigated HCR SNP
association with the disease while stratifying for the presence of
Cw*0602. We found that whatever SNP that was strati®ed for,
there was still a strongly signi®cant Cw*0602 association with
psoriasis. When we stratify for Cw*0602 presence, however, the
only SNP showing signi®cant association (p = 0.001) was +1364
(C®T). Thus, it can be argued that the psoriasis association seen
for several HCR SNP is mainly due to the enrichment of a
Cw*0602 haplotype that contains these SNP. Whereas the majority
of our data supports this, only the results concerning HCR SNP
+1364 appear contradictory. This polymorphism retains psoriasis
association upon strati®cation using Cw*0602 as a confounder. It
should be mentioned that: (i) over 70% of the increase of SNP
+1364 can be attributed to a speci®c Cw*0602 positive haplotype;
(ii) CW*0602 is still a risk factor when stratifying for +1364 (p
= 0.0007); (iii) this polymorphism does not encode an amino acid
change and may have little or no effect on the HCR protein
production; (iv) in the recent Finnish study of HCR psoriasis
association, SNP +1364T (+1229T according to their system) was
actually decreased in psoriasis individuals, which is a strong
argument against +1364 involvement in psoriasis (Asumalahti et
al, 2000). We, therefore, conclude that the HCR gene, in itself, is
unlikely to be a gene involved in the development of psoriasis.
These results may indicate that the true PSORS1 gene is located
between HCR and HLA-C. This is consistent with a recent large-
scale transmission/disequilibrium test, where 339 families were
analyzed using 62 microsatellite markers (Nair et al, 2000). These
analyses indicate that the PSORS1 locus can be narrowed down to
a 60 kb region located between HLA-C and POU5F1.
These results present the problem that all recent candidate genes
in PSORS1 region have now been eliminated. The region
surrounding HLA-C on 6p21 is poor in known genes relative to
the rest of the human major histocompatibility complex, the most
gene-dense region in the genome (The MHC Sequencing
Consortium, 1999). One can, therefore, expect that many as yet
unidenti®ed candidate genes await analysis. The possibility remains
that the PSORS1 locus, however, does not contain a single major
susceptibility gene, but a cluster of alleles that contribute to the
disease in a synergistic manner. To investigate this further, it may
be useful to determine the full extended haplotype that the various
HCR alleles reside upon. Furthermore, the observed ectopic
expression of HCR in psoriasis lesions is an interesting ®nding
(Asumalahti et al, 2000). It may be worthwhile investigating in a
larger number of patients whether this expression is related to any
particular HCR allele. Also, studying the conservation of the
tryptophan residues at AA 103, 109, and 417 in other species may
indicate whether these constitute important AA or if the change to
arginine represents an inconsequential variation.
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